MiRNA-based therapies for the irritable bowel syndrome

Qiqi Zhou, G. Nicholas Verne

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.

Original languageEnglish (US)
Pages (from-to)991-995
Number of pages5
JournalExpert Opinion on Biological Therapy
Volume11
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Irritable Bowel Syndrome
MicroRNAs
Therapeutics
Biological Phenomena
Therapeutic Uses
Metabolism
Epigenomics
Gene expression
Colon
Blood
Clinical Trials
Tissue
Apoptosis
Gene Expression
Molecules

Keywords

  • abdominal pain
  • diarrhea
  • inflammatory bowel disease
  • intestinal permeability
  • irritable bowel syndrome
  • microvesicle
  • miRNA

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

MiRNA-based therapies for the irritable bowel syndrome. / Zhou, Qiqi; Verne, G. Nicholas.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 8, 08.2011, p. 991-995.

Research output: Contribution to journalArticle

Zhou, Qiqi ; Verne, G. Nicholas. / MiRNA-based therapies for the irritable bowel syndrome. In: Expert Opinion on Biological Therapy. 2011 ; Vol. 11, No. 8. pp. 991-995.
@article{dc9ab9ec249f46ad9ec4ea0d5c3c56ca,
title = "MiRNA-based therapies for the irritable bowel syndrome",
abstract = "The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.",
keywords = "abdominal pain, diarrhea, inflammatory bowel disease, intestinal permeability, irritable bowel syndrome, microvesicle, miRNA",
author = "Qiqi Zhou and Verne, {G. Nicholas}",
year = "2011",
month = "8",
doi = "10.1517/14712598.2011.577060",
language = "English (US)",
volume = "11",
pages = "991--995",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - MiRNA-based therapies for the irritable bowel syndrome

AU - Zhou, Qiqi

AU - Verne, G. Nicholas

PY - 2011/8

Y1 - 2011/8

N2 - The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.

AB - The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.

KW - abdominal pain

KW - diarrhea

KW - inflammatory bowel disease

KW - intestinal permeability

KW - irritable bowel syndrome

KW - microvesicle

KW - miRNA

UR - http://www.scopus.com/inward/record.url?scp=79959871196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959871196&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.577060

DO - 10.1517/14712598.2011.577060

M3 - Article

VL - 11

SP - 991

EP - 995

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -